Watchlist Price Alert

Cencora Inc. (COR)

NYSE: COR · Real-Time Price · USD

291.77

-0.35 (-0.12%)

At close: May 05, 2025, 3:59 PM

291.97

0.07%

After-hours: May 05, 2025, 07:35 PM EDT

-0.12% (1D)

Bid	284.89
Market Cap	56.58B
Revenue (ttm)	303.19B
Net Income (ttm)	1.4B
EPS (ttm)	7.04
PE Ratio (ttm)	41.44
Forward PE	16.88
Analyst	Buy

Ask	295
Volume	846,438
Avg. Volume (20D)	1,822,170
Open	293.63
Previous Close	292.12
Day's Range	291.00 - 294.05
52-Week Range	214.77 - 296.65
Beta	0.54

About COR

Cencora, Inc. sources and distributes pharmaceutical products. Its U.S. Healthcare Solutions segment distributes pharmaceuticals, over-the-counter healthcare products, home healthcare supplies and equipment, and related services to acute care hospitals and health systems, independent and chain retail pharmacies, mail order pharmacies, medical clinics, long-term care and alternate site pharmacies, and other customers. The company also provides pha...

[Read more]

Industry Medical - Distribution

Sector Healthcare

IPO Date Apr 4, 1995

Employees 46,000

Stock Exchange NYSE

Ticker Symbol COR

Website https://www.amerisourcebergen.com

Full Company Profile

Analyst Forecast

According to 8 analyst ratings, the average rating for COR stock is "Buy." The 12-month stock price forecast is $285, which is a decrease of -2.32% from the latest price.

Stock Forecasts

Next Earnings Release

Cencora Inc. is scheduled to release its earnings on May 7, 2025, before market opens.
Analysts project revenue of ... Unlock content with Pro Subscription

Why Price Moved

3 weeks ago

+1.92%

Shares of REIT stocks are trading lower amid an ov... Unlock content with Pro Subscription

9 months ago

+2.96%

Cencora shares are trading higher after the company reported better-than-expected Q3 financial results and raised its FY24 adjusted EPS guidance above estimates.

News

15 hours ago · zacks.com

Will Speciality and GLP-1 Drugs Help COR Beat Q2 Earnings Estimates?

COR's fiscal second-quarter results are likely to reflect decent U.S. Healthcare Solutions segmental performance.

3 days ago · zacks.com

Unveiling Cencora (COR) Q2 Outlook: Wall Street Estimates for Key Metrics

Looking beyond Wall Street's top -and-bottom-line estimate forecasts for Cencora (COR), delve into some of its key metrics to gain a deeper insight into the company's potential performance for the qua...

6 days ago · zacks.com

Cencora (COR) Earnings Expected to Grow: Should You Buy?

Cencora (COR) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

2 weeks ago · zacks.com

Is Cencora, Inc. (COR) Outperforming Other Medical Stocks This Year?

Here is how Cencora (COR) and Intensity Therapeutics Inc. (INTS) have performed compared to their sector so far this year.

2 weeks ago · zacks.com

Will Cencora (COR) Beat Estimates Again in Its Next Earnings Report?

Cencora (COR) has an impressive earnings surprise history and currently possesses the right combination of the two key ingredients for a likely beat in its next quarterly report.

2 weeks ago · zacks.com

3 Undervalued Medical Device Stocks to Buy in 2025 Amid Tariff Woes

Here, we discuss three medical device stocks ,COR, HIMS and PBH, that offer cheap valuations, making them attractive bets amid tariff risks.

2 weeks ago · zacks.com

Why Cencora (COR) is a Top Momentum Stock for the Long-Term

Whether you're a value, growth, or momentum investor, finding strong stocks becomes easier with the Zacks Style Scores, a top feature of the Zacks Premium research service.

2 weeks ago · accessnewswire.com

Camino and Nittetsu Complete Acquisition of Permitted Puquios Copper Project in Chile

VANCOUVER, BC / ACCESS Newswire / April 17, 2025 / Camino Minerals Corporation (TSXV:COR)(OTC PINK:CAMZF) ( "Camino" or the "Company" ) is pleased to announce the completion of its previously announce...